US EditionHenlius receives ODD for HLX22 from European Commission
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Henlius receives ODD for HLX22 from European Commission
HLX22 is the first anti-HER2 targeted treatment to receive ODD from both the US Food and Drug Administration (FDA) in March 2025 and from the EU. An international The post Henlius receives ODD for HLX22 from European Commission appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
